Peter Steinberg, MD
Urology · Boston, MANPI 1033227426
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $26,084 of the $26,821 with a category attached, or 97.3%. Boston Scientific accounts for 83.1% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $7,654 and has fallen 62.5% since, to $2,873 in 2025. Among urology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 29 payments — averaging $924.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$22K
- Gyrus ACMI, Inc.$3K
- C. R. Bard, Inc. & Subsidiaries$525
- BD$500
- Urovant Sciences Inc$342
- Alnylam Pharmaceuticals Inc.$267
- plus $205 from 2 others
What the payments were for
- Consulting fees$26,08497%
- Travel & lodging$1721%
- Food & beverage$5642%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 19 | $22,282 |
| Gyrus ACMI, Inc. | 2 | $2,700 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $525 |
| BD | 1 | $500 |
| Urovant Sciences Inc | 1 | $342 |
| Alnylam Pharmaceuticals Inc. | 1 | $267 |
| Calyxo, Inc. | 3 | $173 |
| Steris Corporation | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL KIDNEY STONE DISEASE$10,750
- Soltive$2,700
- Moses 550 D\F\L$2,250
- LithoVue$265
- CVAC Aspiration System$145
How this compares
$26,821 in reported general payments places this provider in the 90th percentile of 327 urology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Potassium Citrate ErPotassium Citrate | 40 | $2,784 |
| Tamsulosin Hcl | 93 | $2,180 |
| Finasteride | 43 | $698 |
| Oxybutynin Chloride ErOxybutynin Chloride | 13 | $465 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 19 | $140 |
Paid to pharmacies, not to this prescriber.
Other urology in Boston
- Christopher CutieBoston$3.5M
- Brian EisnerBoston$424K
- Stephen DretlerBoston$298K
- Tony LuongoBoston$265K
- Ricardo MunarrizBoston$118K
- Mehrdad AlemozaffarBoston$95K
- Adam KibelBoston$92K
- Ruslan KoretsBoston$86K
- Adam FeldmanBoston$74K
- William BoysenBoston$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.